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Summary
In the RIP1-Tag2 mouse model of pancreatic islet carcinoma, angiogenesis is switched on in a discrete premalignant stage
of tumor development, persisting thereafter. Signaling through VEGF receptor tyrosine kinases is a well-established
component of angiogenic regulation. We show that five VEGF ligand genes are expressed in normal islets and throughout
islet tumorigenesis. To begin dissecting their contributions, we produced an islet  cell specific knockout of VEGF-A,
resulting in islets with reduced vascularity but largely normal physiology. In RIP1-Tag2 mice wherein most oncogene-
expressing cells had deleted the VEGF-A gene, both angiogenic switching and tumor growth were severely disrupted, as
was the neovasculature. Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss
is not readily compensated.
Introduction is induction of angiogenesis in the quiescent normal vasculature
of tissues (Hanahan and Weinberg, 2000). The RIP-Tag mouse
It is now widely accepted that tumor growth depends on angio- is one such model (Hanahan, 1985), wherein pancreatic islet
genesis, the formation of new blood vessels. Without the con- carcinogenesis unfolds as a result of expression in pancreatic
comitant growth of new blood vessels (or a means to effectively islet  cells of the SV40 early region, which encodes potent
co-opt existing capillary networks), tumors cannot expand be- large and small T antigen (Tag) oncoproteins. In one particularly
yond a minimal size, invade locally, or metastasize to distant well-characterized line (RIP1-Tag2), T-antigen is expressed in
sites. Angiogenesis, like many biological systems, is under both the developing embryonic pancreas without apparent effect,
positive and negative control, regulated by a balance between until 4–5 weeks of age, when  cell hyperproliferation ensues.
pro- and antiangiogenic molecules. A considerable body of evi- A subset of the resultant hyperplastic and dysplastic islets prog-
ress during the next 5 weeks into “angiogenic islets,” with adence supports the proposition that angiogenesis is initiated
by an angiogenic switch that is tripped when the balance shifts demonstrably activated vasculature (Folkman et al., 1989). A
few weeks later, a few (5–10) encapsulated adenomas emerge,in favor of the angiogenesis inducers (Hanahan and Folkman,
1996). Elucidation of the molecular components of the angio- of which about 25% progress into invasive carcinomas. Angio-
genic islets can be detected both morphologically (in tissuegenic switch will further our understanding of this exquisitely
regulated process, and consequently suggest new therapeutic sections and in physically isolated islets), by their red color and
evident blood islands consequent to microhemorrhaging, andtargets.
Genetically engineered mouse models of cancer have functionally, by their ability to elicit endothelial cell migration,
proliferation, and tube formation in an in vitro collagen gel bio-proven useful in characterizing multistage carcinogenesis (Van
Dyke and Jacks, 2002), in particular for assessing acquired assay involving coculture of dispersed capillary endothelial cells
and isolated pancreatic islets (Folkman et al., 1989).capabilities and the mechanisms that effect them, one of which
S I G N I F I C A N C E
An ongoing challenge for cancer biology and for development of therapeutic strategies that target tumor angiogenesis is to ascertain
the relative contributions of the multitude of angiogenesis regulators that are typically expressed in tumors. Here we demonstrate,
in a strict genetic test, that the angiogenesis inducer VEGF-A has a critical, apparently nonredundant role in the induction of tumor
angiogenesis in a prototypical pathway of multistage carcinogenesis, despite expression of multiple angiogenic regulatory genes.
Notably, no robust, VEGF-A null tumors arose that would have been indicative of functionally compensatory angiogenic signaling.
These results support the focus on VEGF-A and its receptors as a therapeutic target, and suggest that long-term abrogation of VEGF
signaling may not necessarily result in “resistant,” VEGF-A independent tumors.
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Figure 2. All known members of VEGF ligand family are expressed in normal
islets and throughout islet  cell tumorigenesisFigure 1. The complex and overlapping signaling potential of the VEGF fam-
ily of angiogenesis regulators Real-time RT-PCR gene expression analysis of VEGF family members in nor-
mal, nontransgenic islets (N), angiogenic islets (A), and tumors (T) from RIP1-VEGF-A, -B, -C, -D and PLGF bind as indicated to VEGFR-1 and/or VEGFR-2,
Tag2 mice. Data are shown as relative expression compared to normalreceptor tyrosine kinases whose expression largely restricted to endothelial
islets (100%), and were standardized for GAPDH levels.cells. In adults, the related VEGFR-3 is expressed primarily in lymphatic vessels
and can demonstrably regulate lymphangiogenesis; it may also have a
role in developmental angiogenesis. The specificity of VEGF ligand-receptor
interactions depicted here has been recently reviewed by Shibuya et al.
(1999), among others. Results
The pronounced effects of functionally inhibiting VEGF receptor
signaling implicate VEGF ligands in the RIP1-Tag2 tumorigene-
A prominent angiogenesis signaling system has been sis pathway. In previous work we have shown that VEGF-A is
broadly implicated in a variety of cancers, and in particular in expressed constitutively in the pathway, and we have implicated
this model. VEGF-A (a.k.a. VEGF) signals through two trans- its “mobilization” from the ECM by a protease, MMP-9, in angio-
membrane tyrosine kinase receptors selectively expressed on genic switching (Bergers et al., 2000). However, the other VEGF
endothelial cells; VEGF-A has been implicated as a proliferation, family members have all been documented to have angiogenic
migration, and survival factor for endothelial cells, as well as a regulatory activity, and could in principle function as critical
molecule capable of eliciting neovascularization in a variety of ex regulators of angiogenesis in this tumor pathway. The complex
and overlapping nature of the VEGF signaling axis is depictedvivo and in vivo angiogenesis bioassays (Ferrara, 1999). VEGF-A
in Figure 1. In short, all VEGF family members have the potentialis expressed in the  cells of normal islets and at all stages of
to modulate angiogenesis through the binding and activationRIP1-Tag2 tumorigenesis (Christofori et al., 1995). Likewise, the
of VEGFR-1 and/or VEGFR-2. To determine whether any of theVEGF-A receptors, VEGFR-1 and VEGFR-2, are constitutively
other 4 known members of the VEGF family were expressed,expressed in normal islet and Rip1-Tag2 tumor vasculature
we carried out real-time quantitative RT-PCR (Taqman) for(Christofori et al., 1995). This constancy of expression suggests
VEGF-A, -B, -C, -D and PLGF on RNAs isolated from normal,that if VEGF-A activity is important in this tumorigenesis path-
nontransgenic islets, and from angiogenic islets and end-stageway, other modes of regulation must be involved. Indeed, our
tumors from RIP1-Tag2 mice (Figure 2). As expected from ourrecent work has implicated MMP-9 in the proteolytic release of
previous studies, VEGF-A is expressed in all three stages exam-ECM-bound VEGF-A, thereby increasing its bioavailability with
ined. Likewise, the other 4 VEGF family members are expressedresultant activation of angiogenesis (Bergers et al., 2000).
at significant levels in all three stages. Interestingly, the mRNAs
Functional studies have implicated VEGF signaling in angio-
for VEGF-A and PLGF are downregulated in the angiogenic
genesis and tumor growth in the RIP1-Tag2 model. Treatment stages. The significance of this downregulation is unclear, but
of RIP1-Tag2 mice with SU5416 (Vajkoczy et al., 1999), a small it does not result in loss of expression of VEGF protein in the
molecule inhibitor of the VEGF receptors, results in a significant case of VEGF-A. Immunohistochemical analyses of the protein
reduction (90%) in the number of angiogenic islets and in have revealed VEGF-A to be readily detected in normal islets
substantially reduced tumor burden (Bergers et al., 2000). Simi- and in all stages of islet tumorigenesis (Bergers et al., 2000;
lar results were obtained when an adenovirus vector was used Christofori et al., 1995) as well as in medium conditioned by
to deliver a soluble form of VEGFR-1 (sflt) that binds PLGF, angiogenic islets and tumors in organ culture (Christofori et al.,
VEGF-A, and VEGF-B (Compagni et al., 2000). Together, these 1995). The quantitative PCR results reveal that all of the known
results suggest that VEGF ligands play important role in RIP1- VEGF genes are expressed in this pathway, raising the possibil-
Tag2 angiogenesis and tumorigenesis, a hypothesis we have ity that VEGF-receptor mediated angiogenesis might be gov-
erned by some or all of the ligands they encode. We chose tobegun to address.
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Figure 3. Cre-mediated recombinational dele-
tion of the VEGF-flox allele in RIP-Cre mice
The PCR primers used span the floxed region of
the VEGF-A gene such that the PCR product of
the recombined allele is smaller than that of the
nonrecombined allele. As expected, significant
recombination was observed in intact isolated
islets. In addition to islets, brain and testis showed
appreciable recombination, while lung, kidney,
and spleen exhibited low but detectable recom-
bination. There was no apparent phenotypic
consequence to the VEGF gene loss in these
other tissues, which were not targets of onco-
gene expression and resultant neoplasia.
begin a genetic dissection of the functional contribution of these mice were analyzed by staining with Hematoxylin and Eosin
(H&E), by immunostaining with an antibody recognizing the en-angiogenic factors through the use of a tissue specific knockout
of the VEGF-A gene, a strategy motivated by the embryonic dothelial marker PECAM (CD31), and by i.v. perfusion with a
fluorescently labeled lectin (Figure 4). There was no obviouslethality of the germline knockout of this gene (Carmeliet et al.,
1996; Ferrara et al., 1996). alteration in overall islet mass in either RIP-Cre;Vegf fl/ or RIP-
Cre;Vegf fl/fl mice. However, H&E staining suggested a modest
decrease in the density of  cells in RIP-Cre;Vegf fl/fl islets (Fig-Absence of VEGF-A attenuates development
of pancreatic islet vasculature ures 4A–4C). Moreover, a pronounced reduction in blood vessel
density was observed in RIP-Cre;Vegf fl/fl islets, as evidenced byThe bacteriophage Cre/loxP site-specific recombination system
was used to generate a  cell specific VEGF-A null allele. We CD31 and lectin staining (Figures 4D–4I). Lectin perfusion further
revealed that the vasculature in VEGF-A deficient islets exhibitedused a well-characterized transgenic mouse strain (Postic et
al., 1999) in which Cre recombinase is under transcriptional decreased branching in comparison to normal control islets
(Figures 4G–4I). Despite these perturbations in islet vasculariza-control of the rat insulin promoter (RIP-Cre), in combination with
a VEGF-A/loxP mouse line (Gerber et al., 1999), wherein exon tion, glucose homeostasis was normal, and there was no indica-
tion of diabetes (data not shown). The RIP-Cre;Vegf fl/fl mice did3 of the VEGF-A gene is flanked by loxP recombination sites
(“floxed”).  cell expression of the RIP-Cre transgene com- show a modest delay in their response to a bolus intraperitoneal
injection of glucose (a glucose tolerance test), indicating a mildmences during embryogenesis and elicits recombination in ap-
proximately 85% of  cells of adult mice (Kulkarni et al., 1999). defect in glucose sensing or insulin secretion (data not shown).
The viability and general normality of the RIP-Cre;Vegf fl/fl mice,The floxed VEGF allele has been shown to be a very efficient
target of Cre recombinase in multiple tissues (Gerber et al., along with the demonstration of substantial reduction in islet
VEGF expression, afforded the possibility to assess the  cell1999). RIP-Cre;Vegf fl/ and RIP-Cre;Vegf fl/fl mice were gener-
ated, and both were found to be fully viable and indistinguishable specific knockout of VEGF in the context of islet carcinogenesis
in compound RIP-1-Tag2;RIP-Cre;Vegf fl/fl mice.in weight and size from Vegf fl/fl control littermates. In the pres-
ence of Cre recombinase, exon 3 of the floxed VEGF allele was
deleted in the majority of the islet  cells, as revealed by two VEGF-A is critical for angiogenic switching
and tumor growthassays. Genomic DNA derived from isolated islets showed clear
Cre dependent recombination, as evidenced by a PCR-based Beginning at 5–6 weeks of age, hyperplastic/dysplastic islets
in RIP1-Tag2 mice undergo angiogenic switching, evidenced byassay. Recombination was also detected in brain, testis, and,
to a lesser extent, lung, kidney, and spleen (Figure 3), without capillary dilation, sprouting, and microhemorrhaging; the latter
produces the “red islet” phenotype, which is attributed both toapparent phenotypic effect. We suspect that this lack of pheno-
type in non-islet organs reflects Cre expression in only a small blood leaking from the tips of new capillary sprouts and to poor
integrity of the neovasculature. Notably, normal islets are highlysubset of cells in these tissues, and/or that the VEGF-A gene
is not expressed in these cell types in normal, nonpathological vascularized and, as such, angiogenic islets are not scored by
relative increases in vessel density, but rather by these otherconditions. The efficiency of recombinational deletion was also
evident in pancreatic islet sections stained with an anti-VEGF qualities of pathological angiogenesis. To assess the role of
VEGF-A in the angiogenic switch, the angiogenic islets (macro-antibody. VEGF protein levels were comparable in islets from
Vegf fl/fl (Cre) and RIP-Cre;Vegf fl/ mice. In contrast, islets from scopically red in color) were quantified at a defined endpoint
of 10 weeks of age (Figure 5A), much as previously describedRIP-Cre;Vegf fl/fl mice showed markedly reduced immunoreactiv-
ity in most islet cells, although a few scattered cells with appar- (Bergers et al., 1999, 2000). The number of angiogenic islets in
RIP1-Tag2;Vegf fl/fl mice lacking Cre recombinase (n 7) rangedently wild-type VEGF levels were observed (Figures 4J–4L).
These VEGF-positive cells likely represent cells of the other from 12 to 30 (avg.  21.1), similar to traditional Rip1-Tag2
controls. In contrast, RIP1-Tag2/Cre;Vegf fl/fl littermates (n  4)endocrine lineages and/or  cells with nonrecombined floxed
VEGF alleles. typically had only 1 angiogenic islet, with some mice evidencing
none by this assay (P 0.05). RIP1-Tag2/Cre Vegf fl/ (heterozy-To assess the effects of substantially reducing the number of
VEGF-expressing cells on islet morphology and vascularization, gous knockout) mice (n 4) had a similar number of angiogenic
islets to control RIP1-Tag2;Vegf fl/fl (Cre) mice, suggesting thatpancreatic sections from RIP-Cre;Vegf fl/ and RIP-Cre;Vegf fl/fl
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Figure 4. VEGF-A is involved in normal islet vascularization
A–C: Hematoxylin and Eosin staining reveals a slight increase in the cytoplasmic/nuclear ratio of Rip-Cre;Vegf fl/ (B) and Rip-Cre;Vegf fl/fl (C) islets when
compared to wild-type islets (A).
D–F: CD31 (PE-CAM) was used to visualize the islet capillaries; wild-type (D) and Rip-Cre;Vegf fl/ (E) islets are indistinguishable. In contrast, the islets of Rip-
Cre;Vegf fl/fl mice had a marked decrease CD31 immunoreactivity, which is most evident in the interior of the islets (F).
G–I: Blood vessel staining by lectin perfusion revealed the vascular density to be significantly decreased in Rip-Cre;Vegf fl/fl (I) but not in Rip-Cre;Vegf fl/
islets (H) compared to the control islets (G).
J–L: VEGF immunostaining assessed the effects of the cre-mediated recombination on VEGF-A gene expression. Wild-type (J) and Rip-Cre;Vegf fl/ islets (K)
exhibited strong homogeneous staining, while Rip-Cre;Vegf fl/fl islets (L) had a considerably reduced level of staining. The images presented are representative
of the analysis of three mice and at least 10 islets per mouse.
one functional allele of VEGF-A is sufficient for angiogenic islet ence emerged: RIP1-Tag2/Cre;Vegf fl/fl mice had a mean collec-
tive tumor volume of 3 mm3, whereas control RIP1-Tag2;Vegf fl/flformation.
Next we assessed tumor number and tumor burden at a mice had an average burden of 63.5 mm3 (P  0.05) (Figure
5C). Interestingly, while RIP1-Tag2/Cre;Vegf fl/ (heterozygousdefined endpoint of 12-week-old animals (Figures 5B and 5C). In
control RIP1-Tag2;Vegf fl/fl (Cre) animals (n 16), tumor number knockout) mice (n  9) had no significant difference in tumor
number (or angiogenic islet number) compared to control, tumorranged from 2 to 10, as it did in RIP1-Tag2/Cre;Vegf fl/ mice
carrying a nonfloxed wild-type VEGF allele that was not suscep- burden was significantly reduced (P  0.05) (Figure 5C), sug-
gesting that tumor growth is more sensitive to reduced VEGFtible to inactivation by Cre-mediated recombination. In contrast,
RIP1-Tag2/Cre;Vegf fl/fl mice (n 7) had 0 to 3 tumors detectable dose than is angiogenic switching in progenitor lesions or initial
formation of small solid tumors. Of course, an alternative inter-by gross pathology (Figure 5B). When tumor burden was as-
sessed in these same animals, an even more remarkable differ- pretation is that the tumor development pathway is merely de-
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number at 16 weeks from that observed at 12 weeks. Thus, both
formation and growth of solid tumors were not just temporally
delayed, but rather were significantly impaired by the absence
of VEGF-A.
Three classes of tumor were revealed in RIP1-Tag2/
Cre;Vegf fl/fl mice by gross pathology and subsequent histologi-
cal analysis: (1) solid tumors similar in appearance to tumors in
wt mice (red in color); (2) soft tumor masses that were black in
color; and (3) small tumor lesions detectable only microscopi-
cally. The existence of such disparate lesions raised a question:
was the VEGF gene deleted in all three classes? To assess
the occurrence of Cre mediated recombination that converted
Vegf fl/fl alleles into deleted Vegf/ alleles, tumor DNA from class
1 and 2 tumors (which can be easily identified and isolated by
dissection of the pancreas) was prepared and analyzed using
a PCR-based assay. Six independent tumors from three RIP1-
Tag2/Cre; Vegf fl/fl mice were examined; 4 out of 6 tumors had
no detectable recombination. Importantly, these tumors were
of the class 1 type, being relatively large, bright red, and solid.
Histological analysis of the class 1 tumors having an intact,
functional floxed VEGF allele indicated they were morphologi-
cally indistinguishable from wt RIP1-Tag2 and RIP1-Tag2/
Cre;Vegf/ tumors (Figures 6A and 6C); moreover, the class
1 tumors had equivalent vessel densities to control tumors,
as assessed by CD31 staining (Figures 6B and 6D). No Cre
immunoreactivity was observed in class 1 tumors with an intact
VEGF allele (data not shown), suggesting that the RIP-Cre trans-
gene was transcriptionally silenced, mutated, or deleted entirely.
These data are consistent with prior observations that only
85% of the  cells in mice of the particular RIP-Cre line used
in this study exhibited recombination of several other floxed
gene alleles and “reporter” constructs (Gannon et al., 2000).
Our VEGF immunostaining of pancreatic sections from RIP-
Cre;Vegf/ mice also revealed a small number of Cre negative
but VEGF positive cells, which could well be the progenitors of
the class 1 “escapee” tumors.Figure 5. VEGF-A is instrumental in angiogenic switching and tumor growth
The class 2 tumors evidenced recombinational deletion ofA: The incidence of angiogenic islets is compared at 10 weeks of age,
when about 10% of Rip1-Tag2 islets have switched on angiogenesis. B: The both floxed VEGF alleles (Figure 6) and a morphology never
number of tumors was determined at 12 weeks of age, comparing Rip1- observed in wt RIP1-Tag2 or in RIP1-Tag2/Cre;Vegf/ control
Tag2/Cre;Vegf/, Rip1-Tag2/Cre;Vegf fl/, and Rip1-Tag2/Cre;Vegf fl/fl mice. mice. The class 2 tumors were essentially hollow, with a thin
C: Tumor burden at 12 weeks of age is presented. D: Comparing the number
shell of viable tumor cells at the periphery and a core filled withof tumors at 14 weeks in Rip1-Tag2/Cre;Vegf/ with that at 16 weeks of
red blood cells (Figure 6E). Although RIP1-Tag2 tumors areage in Rip1-Tag2/Cre;Vegf fl/fl mice. (The wt RIP1-Tag2 mice die at 14 weeks,
while the Rip1-Tag2/Cre;Vegf fl/fl mice live longer, allowing for possible new hemorrhagic and have multiple blood islands, these islands
tumor formation and continuing tumor growth). E: Tumor burden is com- never fuse to form such large hollow structures. The hollow
pared at 14 weeks of age for Rip1-Tag2/Cre;Vegf/ mice and 16 weeks
tumor core could result from necrosis or massive apoptosis asof age for Rip1-Tag2/Cre;Vegf fl/fl mice.
a consequence of poor oxygen and nutrient supply, resulting
from a dysfunctional vasculature. Blood vessels were infre-
quently observed within the shells of viable tumor cells at the
periphery of the class 2 tumors, and more often were evidentlayed, such that a similar number of tumors would eventually
at the interface of the surrounding exocrine tissue (Figure 6F),form.
perhaps representing co-option of preexisting normal pancre-To assess the latter possibility, that lack of VEGF-A function
atic vessels by the tumor cells (Holash et al., 1999a). The thick-was merely delaying the tumor development pathway at all
ness from the outer edge to the inner edge of the viable ringstages, we assessed tumor number and tumor burden at 16
of tumor cells was typically 100 m, about the diffusion limitweeks of age, two weeks on average after the mice with wt VEGF
of oxygen from those peripheral vessels.alleles died (Figures 5D and 5E). This analysis was afforded
The class 3 tumors were smaller than the class 1 and 2by the observation that RIP1-Tag2/Cre;Vegf fl/fl animals survived
tumors (less than 2 mm) and could only be detected microscopi-longer than controls. Sixteen week old RIP1-Tag2/Cre;Vegf fl/fl
cally. However, they were very similar in morphology to the(n  6) mice exhibited a 5-fold reduction in tumor number (P 
class 2 tumors, as determined by both H&E staining and lectin0.05), and a 6-fold reduction in tumor burden (P  0.05) com-
perfusion (Figures 7B, 7C, 7E, and 7F). Like the macroscopicpared to the control mice (n  5) at their end stage of 14 weeks
of age. Remarkably, there was no significant increase in tumor class 2 tumors, these lesions had avascular cores and often
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Figure 6. The exceptional large, well-vascularized tumors in Rip1-Tag2;Rip-Cre;Vegffl/fl mice retain VEGF-A expression
The first column presents the germline genotype as determined by PCR analysis of tail-derived genomic DNA. The second column presents the data on
tumor genotype (Rec  recombination of the floxed VEGF allele; n-Rec  nonrecombination of the floxed VEGF allele), as determined by PCR analysis of
genomic DNA from liver (N) and tumor (T). The third and fourth columns represent H&E and CD31 staining of adjacent serial sections, respectively. A and
B: A wt (Class 1) tumor exhibiting a dense, uniform vasculature that developed in a Rip1-Tag2/Cre;Vegf/ control mouse (i.e., one that lacked floxed
VEGF alleles). C and D: A Class 1 tumor from a Rip1-Tag2/Cre;Vegf fl/fl mouse in which the VEGF-flox alleles were not recombined, allowing normal VEGF
expression. E and F: A markedly distinct tumor from a Rip1-Tag2/Cre;Vegf fl/fl mouse in which the VEGF floxed alleles appear to be completely recombined.
H&E staining reveals the hollow nature of these (Class 2) tumors, and CD31 staining indicates that the vessels are largely restricted to the tumor perimeter.
Scale bar, 100 m.
exhibited a “hollow” tumor phenotype (Figure 7F), even in tumor which of these molecules and signaling circuits govern angio-
genesis in particular situations. Mouse models represent a pow-lesions less than .5 mm in diameter (Figure 7C). The vessel
density was highest at the periphery of these lesions, again erful tool to address this issue, since angiogenic pathologies
can be induced, and candidate genes genetically ablated tosuggesting that the growing tumor may co-opt the neighboring
vessels of the surrounding exocrine pancreas. Other micro- assess the consequences of their absence, as we have illus-
trated herein.scopic lesions lacked hollow cores but nevertheless exhibited
reduced vessel density (Figure 7E) compared to lesions of the VEGF signaling has been clearly implicated in angiogenesis
and tumorigenesis in Rip1-Tag2 mice: a soluble VEGFR-1 re-same size in Rip1-Tag2 control mice (Figure 7D). All tumors 
2 mm in diameter were either highly vascularized (VEGF-A) ceptor impairs tumor angiogenesis and tumor growth (Com-
pagni et al., 2000), as does pharmacological inhibition of VEGF-class 1 or hollow, poorly vascularized (VEGF null) class 2 tumors.
R2 (Bergers et al., 1999). Furthermore, ectopic overexpression
of VEGF-A via a RIP-VEGF transgene in the context of RIP-Discussion
Tag tumorigenesis enhances angiogenic switching and tumor
growth (Gannon et al., 2002). Now we have clearly shown thatAn extensive literature has documented the involvement of li-
gand/receptor signaling circuits in both physiological and patho- among the 5 VEGF-receptor ligand genes found to be expressed
in normal islets, VEGF-A itself is profoundly important not onlylogical angiogenesis. Most of these circuits are composed of
ligand and receptor families whose members have both inde- for angiogenic switching, but also for tumor formation and tumor
growth in this model of  cell carcinogenesis. The tissue specificpendent and overlapping functions. The challenge is to ascertain
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Figure 7. Lectin perfusion reveals an impaired vasculature in the microscopic tumor lesions of Rip1-Tag2/Cre;Vegf fl/fl mice
All panels visualize the vascular density and morphology of microscopic Rip1-Tag2 tumors by lectin staining. A: A small, microscopic (nascent) tumor lesion
(less than .5 mm in diameter) from a control Rip1-Tag2/Cre;Vegf/ mouse. B: In a Rip1-Tag2/Cre;Vegf fl/fl pancreas, vascular density was dramatically
decreased in the core of similarly sized nascent tumors, with some showing nearly complete absence of blood vessels. C: In many of these microscopic
tumor lesions, the hollow tumor phenotype was also evident. Inset, H&E staining of a hollow islet tumor. D: A typical, medium sized microscopic tumor (.5
mm to 1.5 mm in diameter) in a control Rip1-Tag2/Cre;Vegf/ mouse, which is well vascularized and not hollow. E: A similarly sized Rip1-Tag2/Cre;Vegf fl/fl
tumor, in which vessel density is significantly reduced. F: Most microscopic tumors in Rip1-Tag2/Cre;Vegf mice exhibit a “hollow” tumor phenotype. Scale
bar, 100 m.
knockout of VEGF-A severely impairs angiogenic switching in tumor-derived VEGF-A function in a similar autocrine loop? An
accumulation of evidence suggests that VEGF is not acting asprogenitor hyperplastic and dysplastic lesions, as well as their
progression to solid tumors. Importantly, there is no evidence an autocrine tumor growth factor for islet carcinogenesis: (1)
soluble VEGF-R1 delivered by an adenovirus vector is a potentof alternative compensatory pathways that can substitute for
VEGF-A deficiency. The proof here is in the exception: robust inhibitor of RIP-Tag tumor growth in vivo, but has no effect on the
growth of RIP-Tag tumor cell lines (TC) in culture (Compagni etsolid tumors are observed, but these are infrequent “escapees”
from Cre-mediated deletion that manage to retain intact VEGF al., 2000); (2) forced overexpression of VEGF-A165 via a RIP-
VEGF transgene accelerates the onset of RIP-Tag tumor angio-alleles. We have not observed robust tumors that are VEGF
null, which would be indicative of an alternative compensatory genesis, but has no effect on tumor cell proliferation or apoptosis
(Gannon et al., 2002); (3) in situ hybridization and immunostain-pathway. This is remarkable, since normal and neoplastic islets
express multiple angiogenic growth factor genes, including ing analysis of both normal and RIP-Tag pancreas indicates
that VEGF-R1/R2 expression is detectable only in the islet vas-10–12 members of the FGF family (Christofori and Luef, 1997;
Compagni et al., 2000; Hart et al., 2000; J. Joyce and D.H., culature (Bergers et al., 2000; Christofori et al., 1995; Lammert
et al., 2001); and (4) expression of the key signaling receptor,unpublished data) in addition to all five members of the VEGF
family. Among the candidate FGFs, ablation of a perennial can- VEGF-R2, was not detected by RT-PCR analysis of 5 indepen-
dent islet tumor-derived (TC) cell lines, whereas VEGF-R1 anddidate, FGF-1, via crosses to FGF-1 knockout mice had no
impact on angiogenic switching or tumor growth (D.H., M. Singh, VEGF-R3 mRNA were detectable, but only in a subset of these
same tumor cell lines, and at very low levels (J.H.H., unpublishedet al., unpublished data).
The dramatic impact of the VEGF-A gene knockout on the data). Furthermore, when primary tumors were separated into
constituent cell types by flow cytometry, real-time quantitativetumor phenotype naturally raises the question of whether the
effects are wholly consequential to vascular dysfunction. In- RT-PCR analysis of mRNA revealed that VEGF-R2 and R1 were
expressed at 40–50 fold higher levels in the endothelial celldeed, it is now becoming apparent that the VEGF receptors are
not strictly endothelial cell specific in their expression, and there fraction versus the other highly purified (but not pure) cell frac-
tions (D.H., N. Meyer-Morse, et al., unpublished data). Collec-is evidence for autocrine VEGF signaling via VEGF receptors
expressed in certain tumor cell lines. For example, coexpression tively, the evidence clearly suggests that VEGF-A functions as
a modulator of angiogenesis and not as an autocrine growthof VEGF-A, VEGF-R1, and VEGF-R2 has been detected in the
tumor cells of primary pancreatic ductal adenocarcinomas factor in this setting. Engineering a  cell specific “KO” of VEGF-
R1/2 in the context of RIP-Tag tumorigenesis would definitively(PDAC) and in cultured PDAC tumor cell lines (Itakura et al.,
2000; Luo et al., 2001); the growth of PDAC cell lines could be test whether VEGF-A has some subtle autocrine contribution
to tumor growth.attenuated when transfected with antisense VEGF-A or en-
hanced when exposed to exogenous VEGF-A. Might RIP-Tag The results of ablating VEGF-A have several implications.
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The first involves nonredundancy and lack of functional com- recognize that the VEGF gene knockout was present throughout
tumorigenesis in this study, and thus most accurately mimics apensation amongst the family of VEGF ligand genes expressed
in this pathway. Quantitative PCR analysis has revealed that completely efficacious cancer prevention trial targeting VEGF-A.
Notably, preclinical trails in the RIP-Tag model of a pharmaco-VEGF-B, -C, -D, and PLGF are all expressed in normal islets
and throughout RIP1-Tag2 tumorigenesis. The results indicate logical inhibitor of VEGF-R2 (SU5416) revealed similar reduc-
tions in the initial induction of angiogenesis (angiogenic switch-that no other member of the VEGF gene family can substitute
for lack of VEGF-A function insofar as they are expressed during ing frequency) in the still quiescent vasculature of hyperplastic/
dysplastic lesions, and similar restrictions of nascent tumorislet tumorigenesis (Figure 2). Some of us have previously re-
ported apparent compensatory upregulation of VEGF-A and growth (Bergers et al., 2000); in both trials, treatment was initi-
ated early in disease progression. Thus, both the gene knockoutPLGF following treatment of an orthotopic tumor with anti-
VEGF-A therapy (Gerber et al., 2000). In the RIP1-Tag2 model, and the “pharmacological knockout” of VEGF-A signaling in the
RIP-Tag model predict that VEGF inhibitors could have value asthe absence of compensation could result from a lack of suffi-
cient transcriptional upregulation (Gerber et al., 2000), or from stand-alone agents in pharmacological prevention of incipient
neoplasia. By contrast, the VEGF-R inhibitor did not producea lack of ligand mobilization by proteolysis as occurs for VEGF-A
(Bergers et al., 2000), or from an absence of functional overlap an objective response (tumor regression) when it was used to
treat large, well-established islet tumors in RIP1-Tag2 micein signaling. Certainly further studies on protein levels, isoforms,
and bioavailability of VEGF-B, -C, -D, and PlGF are warranted, (D.H., G. Bergers, et al., unpublished data), not unlike several
other angiogenesis inhibitors (Bergers et al., 1999). Similarly,both in the wt and VEGF-A/null situations. Indeed, it would not
be surprising to find that another VEGF ligand has an important the ongoing clinical trials of agents that inhibit VEGF-A or its
receptors against late stage human tumors do not appear torole in this tumorigenesis pathway, functioning as a “cofactor”
or potentiator of VEGF-A signaling that is not itself sufficient to be producing dramatic results. While most of the definitive trials
are still in progress and hence unpublished, it is pertinent to“trip” the angiogenic switch or sustain tumor angiogenesis in
the absence of VEGF-A. Interestingly, it has been recently re- note the case of SU5416, which has recently been withdrawn
from Phase III trials, a decision motivated in part a lack ofported that overexpression of VEGF-C in the islet  cells via a
RIP-VEGF-C transgene induces peri-islet lymphatic vessels but objective responses against late stage colon cancer (Press Re-
lease, Pharmacia Corp., Feb. 8, 2002; http://www.pharmacia.has no discernable effect on intra-islet blood vessels (Mandriota
et al., 2001). Likewise, in the context of RIP1-Tag2 tumorigene- com/News/NewsDisplay.asp?PR267). One explanation of
these disappointing results with SU5416 in both mouse andsis, VEGF-C overexpression did not increase intra-tumoral vas-
cularity or enhance tumor growth; instead, peri-tumoral lym- human trials is that late stage tumors can activate additional
angiogenic regulatory circuits which function in concert withphatic vessels induced by VEGF-C facilitated metastases to the
draining mesenteric lymph nodes (Mandriota et al., 2001). This or independent of VEGF-A/VEGF-R2 signaling, reducing their
VEGF dependence. If so, one must infer that the VEGF-A/nullresult argues that VEGF-C functions primarily to regulate lymph-
angiogenesis and not tumor blood vessel growth in the RIP- tumors described above never achieve this late stage of pro-
gression where VEGF-A activity is less singular. A second, quiteTag model, a hypothesis that awaits evaluation via a more defin-
itive loss-of-function study. Likewise, the systematic genetic plausible explanation is that tumor angiogenesis remains highly
dependent on VEGF-A signaling in late stage cancers, but theablation of PLGF, VEGF-B, and VEGF-D should reveal contribu-
tions by these molecules to this prototypical pathway of tumori- current formulations of VEGF-A and VEGF-receptor inhibitors
do not achieve complete blockade of VEGF-A signaling insidegenesis.
A growing body of data suggests that carcinoma cells can well-established, solid tumors. If so, then future improvements
in bioavailability and pharmacodynamics of VEGF-A/VEGF-Rinvade into normal tissue, enveloping, or co-opting, quiescent
blood vessels to sustain their survival and proliferation (Holash inhibitors in cancerous lesions could affect a complete pharma-
et al., 1999a, 1999b; Pezzella et al., 1997). Apparent vessel co- cological knockout of VEGF-A function, enabling such drugs to
option has been observed during histopathological analysis of achieve results analogous to those we report for the VEGF-A
human tumors (Pezzella et al., 1997) and tumor xenotransplant gene knockout. Nevertheless, it seems likely that other angio-
models (Holash et al., 1999a; Kunkel et al., 2001; Rubenstein genic signaling circuits make important qualitative or quantita-
et al., 2000), and there is reason to suspect that co-option has tive contributions to the vascularization of tumors as they prog-
the potential to predominate when angiogenesis is suppressed, ress; indeed, FGF signaling is implicated from therapeutic trials
as a consequence of tissue microenvironment or pharmacologi- with a functional inhibitor in the RIP-Tag model (Compagni et al.,
cal inhibition. Indeed, we suspect that co-option is involved in 2000). Looking forward, combinatoric inhibition both of VEGF-A
the survival of a thin rim of tumors cells at the periphery of the signaling and of those angiogenic regulatory circuits that en-
hollow, type II/III islet tumors, where the tumor cells appear to hance or complement VEGF in particular tumor types, perhaps
be in close apposition to preexisting vessels of the surrounding along with blockade of the invasive program that co-opts normal
exocrine pancreas. It follows that the RIP-Tag/VEGF null model vessels, could present a powerful strategy for treating human
could prove useful for studying vessel co-option and preclinical cancers.
testing of treatment strategies that might abrogate it.
Experimental procedures
Implications for human cancer therapy
Real-time quantitative RT-PCR of VEGF familyIn summary, our genetic analysis of VEGF-A gene function dur-
member expression
ing islet tumorigenesis encourages the ongoing development Total RNA from normal, nontransgenic islets and from angiogenic islets and
of pharmacological inhibitors of VEGF signaling in general, and tumors from RIP1-Tag2 mice was isolated using the STAT 60 method (TEL-
TEST “B,” Friendswood, TX) and purified on RNeasy Quick spin columnsof the VEGF-A ligand in particular. It is, however, important to
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(Qiagen, Valencia, CA). Probe primer sequences for all genes except VEGF-D was about 1800 bp, while the recombined allele was about 200 bp. Primer
sequences were VEGF419F (5-CCTGGCCCTCAAGTACACCTT-3) andand real-time RT-PCR conditions, as well as methods applied for data analy-
sis, were as described previously (Gerber et al., 2000). A total of 100 ng of VEGFc5R2 (5-ACATCTGCTGTGCTGTAGGAAG-3).To assess recombina-
tional deletion of VEGF-A in tumors, a segment of the tumor tissue wastotal RNA was used per RT-PCR reaction. RNA levels were standardized to
the probe/primer set for murine GAPDH. For linear regression, total RNA excised (prior to embedding the remainder for histopathological analyses),
from which DNA was extracted, and analyzed for recombination using thefrom adult mouse liver (Clonetech, Palo Alto, CA) was used. Oligo sequences
for RT-PCR analysis of murine VEGF-D were: probe, (MMVEGFD.1326.T) PCR assay.
ACATTTCCATGCAATGGCGGCT; forward primer, (MMVEGFD.1302.F)
TTGACCTAGTGTCATGGTAAAGC; and reverse primer, (MMVEGFD.1369.R) Acknowledgments
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